Pacific Biosciences 주식 (NASDAQ: PACB)

에 대한 최신 뉴스 Pacific Biosciences (NASDAQ:PACB) 주식

PACIFIC BIOSCIENCES OF CALIF

Pacific Biosciences

Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.

Cathie Wood Offloads Meta Stock While Mark Zuckerberg Celebrates Llama AI Success

Equities

News

Markets

ETFs

ABSI

AMGN

ARKG

ARKK

ARKQ

ARKX

BEAM

ILMN

IRDM

PACB

RPTX

VEEV

2025년 3월 21일 금요일, 캐시 우드가 이끄는 아크 인베스트는 몇 가지 주목할 만한 거래를 진행했으며, 여기에는 상당한 매수와 매도가 포함되었다. 아크 인베스트의 펀드는 이리듐 커뮤니케이션스(NASDAQ:IRDM), 빔 테라퓨틱스(NASDAQ:BEAM), 퍼시픽 바이오사이언스 오브 캘리포니아(NASDAQ:PACB), 및 앱시 코퍼레이션(NASDAQ:ABSI)를 매수한 반면, 일루미나(NASDAQ:ILMN), 리페어 테라퓨틱스(NASDAQ:RPTX), 암젠(NASDAQ:AMGN), 및 비바 시스템즈(NYSE:VEEV)의 주식을 매도했다.

아크 인베스트가 이리듐·빔·퍼시픽 바이오사이언스를 매수, 일루미나와 암젠을 매각

Pacific Biosciences of California, Inc. - Common Stock

Pacific Biosciences of California Inc

6 analysts have expressed a variety of opinions on Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $2.04, a high estimate of $2.50, and a low estimate of $1.50. Observing a downward trend, the current average is 30.14% lower than the prior average price target of $2.92. 
<img src="https://www.benzinga.com/files/images/story/2025/1742929238_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Pacific Biosciences. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$2.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$2.00</td>
<td>$2.50</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$1.50</td>
<td>$1.75</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$2.50</td>
<td>$2.50</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$2.50</td>
<td>$2.50</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$1.75</td>
<td>$2.25</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Pacific Biosciences. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Pacific Biosciences compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Pacific Biosciences's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Pacific Biosciences's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PACB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Pacific Biosciences analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Pacific Biosciences: A Closer Look</h2>
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
<h3>A Deep Dive into Pacific Biosciences's Financials</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Pacific Biosciences's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -32.79%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Pacific Biosciences's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.04% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Pacific Biosciences's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.49% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Pacific Biosciences's ROA stands out, surpassing industry averages. With an impressive ROA of 0.17%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.33, caution is advised due to increased financial risk.
<h2>What Are Analyst Ratings?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Assessing Pacific Biosciences: Insights From 6 Financial Analysts

Scotiabank analyst Sung Ji Nam maintains Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) with a Sector Outperform and lowers the price target from $6 to $2.

Price Target

Scotiabank Maintains Sector Outperform on Pacific Biosciences, Lowers Price Target to $2

On Friday, March 21, 2025, the Cathie Wood-led Ark Invest made some notable trades, including significant buys and sells.
Ark Invest's fund bought Iridium Communications Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRDM#NASDAQ">IRDM</a>), Beam Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>), Pacific Biosciences of California Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) and Absci Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>), while selling Illumina Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), Repare Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>), Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), and Veeva Systems Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>).
The IRDM Trade: Ark Invest&#8217;s ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>), ARK Autonomous Technology &amp; Robotics ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKQ#BATS">ARKQ</a>), and ARK Space Exploration &amp; Innovation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKX#BATS">ARKX</a>) funds purchased a total of 68,355 shares of Iridium Communications Inc.
The total value of the shares bought, based on the last close price of $27.65, is approximately $1.89 million.
The BEAM Trade: Ark Invest&#8217;s ARKK and Ark Genomic Revolution ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>) funds bought a total of 28,717 shares of Beam Therapeutics Inc.
The total value of the shares bought, based on the last close price of $23.3, is approximately $669,106.
The PACB Trade: Ark Invest&#8217;s ARKK fund bought a whopping 243,300 shares of Pacific Biosciences of California Inc.
The total value of the shares bought, based on the last close price of $1.3, is approximately $316,290.
Other Key Trades:
<ul>
<li>Illumina Inc: Ark Invest sold a total of 42,616 shares through ARKK and ARKG.</li>
<li>Absci Corp: Ark Invest&#8217;s bought 71,392 shares through ARKG.</li>
<li>Repare Therapeutics: Ark Invest sold 54,786 shares through ARKG.</li>
<li>Amgen Inc: Ark Invest sold 990 shares through ARKG.</li>
<li>Veeva Systems Inc: Ark Invest sold 1,322 shares through ARKG.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/03/44434973/tesla-record-highest-trade-ins-amid-backlash-against-ceo-elon-musk-surge-in-vandalism">Tesla Record Highest Trade-Ins Amid Backlash Against CEO Elon Musk, Surge In Vandalism</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Cathie Wood's Ark Invest Scoops Up Iridium, Beam, Pacific Biosciences While Offloading Illumina And Amgen

Piper Sandler analyst David Westenberg reiterates Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) with a Neutral and lowers the price target from $2.5 to $2.

Reiteration

Piper Sandler Reiterates Neutral on Pacific Biosciences, Lowers Price Target to $2

In the last three months, 4 analysts have published ratings on Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>), offering a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $2.06, a high estimate of $2.50, and a low estimate of $1.50. Experiencing a 8.44% decline, the current average is now lower than the previous average price target of $2.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1739908820_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Pacific Biosciences. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$1.50</td>
<td>$1.75</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$2.50</td>
<td>$2.50</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$2.50</td>
<td>$2.50</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$1.75</td>
<td>$2.25</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Pacific Biosciences. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Pacific Biosciences compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Pacific Biosciences's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Pacific Biosciences's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/PACB/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Pacific Biosciences analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Pacific Biosciences</h2>
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
<h3>Pacific Biosciences: Financial Performance Dissected</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Pacific Biosciences's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -28.23% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -151.94%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -12.84%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Pacific Biosciences's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -4.1%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a high debt-to-equity ratio of 2.03, Pacific Biosciences faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Pacific Biosciences Stands With Analysts

Goldman Sachs analyst Matthew Sykes maintains Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) with a Neutral and lowers the price target from $1.75 to $1.5.

Goldman Sachs Maintains Neutral on Pacific Biosciences, Lowers Price Target to $1.5

Stephens &amp; Co. analyst Mason Carrico reiterates Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) with a Overweight and maintains $2.5 price target.

Stephens & Co. Reiterates Overweight on Pacific Biosciences, Maintains $2.5 Price Target

WIIM

Pacific Biosciences shares are trading higher after a 13F filing showed SoftBank Group took a new stake of 20.45 million shares.

Pacific Biosciences of California shares are trading higher after the company reported better-than-expected Q4 adjusted EPS results. Also, Softbank added 20.45M shares in the company.

<a href="https://www.sec.gov/Archives/edgar/data/1065521/000106299325002489/xslForm13F_X02/form13fInfoTable.xml" title="https://www.sec.gov/Archives/edgar/data/1065521/000106299325002489/xslForm13F_X02/form13fInfoTable.xml">https://www.sec.gov/Archives/edgar/data/1065521/000106299325002489/xslForm13F_X02/form13fInfoTable.xml</a>

BETR

DASH

IONQ

LMND

NMRA

NVDA

RXRX

SFTBY

TMUS

VTEX

WBTN

SoftBank Group 13F Update: New 14.67M Share Stake In Recursion Pharmaceuticals, 20.45M Shares In Pacific Biosciences, 628.55K Shares In Better Home & Finance; Dissolved 5.68M Shares Stake In Exscientia, 1.59M Shares In IonQ, 23.38K Shares In DoorDash; Increased Stakes in T-Mobile, Nvidia, Webtoon, VTEX, YMM; Decreased Stakes In Lemonade, Nu Holdings, Neumora, Symbotic

U.S. stocks were mostly lower, with the Dow Jones falling around 100 points on Friday.
Shares of The Goodyear Tire &amp; Rubber Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GT#NASDAQ">GT</a>) rose sharply during Friday's session after the company reported better-than-expected <a href="https://www.benzinga.com/quote/GT/analyst-ratings">quarterly financial results</a>.
Goodyear Tire &amp; Rubber reported quarterly earnings of 39 cents per share which beat the analyst consensus estimate of 31 cents per share. The company reported quarterly sales of $4.95 billion which beat the analyst consensus estimate of $4.87 billion.
Goodyear Tire &amp; Rubber shares jumped 19.4% to $9.76 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>WeRide Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRD#NASDAQ">WRD</a>) shares jumped 97.7% to $33.94 after Nvidia disclosed a stake of 1.74 million shares in a 13F filing.</li>
<li>Nu Skin Enterprises, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUS#NYSE">NUS</a>) gained 34.6% to $8.65 following upbeat quarterly earnings.</li>
<li>Udemy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UDMY#NASDAQ">UDMY</a>) gained 23.7% to $9.67 after the company reported fourth-quarter earnings and revenue above estimates.</li>
<li>Pacific Biosciences of California, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) rose 20.9% to $1.7900 following upbeat quarterly earnings.</li>
<li>Kingsoft Cloud Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) gained 20.3% to $20.86.</li>
<li>Personalis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>) gained 17.2% to $5.85.</li>
<li>TreeHouse Foods, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THS#NYSE">THS</a>) gained 17% to $38.90 following fourth-quarter results.</li>
<li>Pony AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) climbed 16% to $17.25.</li>
<li>Airbnb, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) gained 15.8% to $163.43 following a quarterly revenue beat. Multiple analysts upgraded the stock following the report.</li>
<li>Roku, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) rose 15.2% to $100.00 following better-than-expected quarterly financial results.</li>
<li>Beam Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) gained 14.8% to $32.85.</li>
<li>CAE Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAE#NYSE">CAE</a>) rose 14.7% to $26.98 after the company reported a year-over-year increase in third-quarter financial results.</li>
<li>DraftKings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) gained 13.3% to $52.62 after the company reported better-than-expected quarterly adjusted EPS results and raised its FY25 revenue guidance.</li>
<li>West Pharmaceutical Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) rose 11.2% to $221.56.</li>
<li>Pilgrim&#8217;s Pride Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPC#NASDAQ">PPC</a>) gained 9.6% to $57.07.</li>
<li>Tencent Music Entertainment Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TME#NYSE">TME</a>) rose 5.3% to $13.43</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43692962/top-3-consumer-stocks-you-may-want-to-dump-in-february">Top 3 Consumer Stocks You May Want To Dump In February</a></li>
</ul>

Intraday Update

Movers

Trading Ideas

ABNB

DKNG

PONY

PSNL

ROKU

UDMY

Goodyear Tire & Rubber Posts Upbeat Results, Joins Nu Skin, Pacific Biosciences of California, Airbnb, Roku And Other Big Stocks Moving Higher On Friday

Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.21) by 4.76 percent. This is a 25.93 percent increase over losses of $(0.27) per share from the same period last year. The company reported quarterly sales of $39.22 million which missed the analyst consensus estimate of $40.16 million by 2.33 percent. This is a 32.79 percent decrease over sales of $58.36 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Pacific Biosciences Q4 Adj $(0.20) Beats $(0.21) Estimate, Sales $39.22M Miss $40.16M Estimate

AENT

AGIO

ALNY

AMAT

APDN

ATUS

AVNT

BENF

BFAM

BLIN

BPMC

BRKR

BTOC

CBRE

CEVA

CLBT

CNVS

COHU

COIN

CROX

CYBR

DDOG

DNOW

DXCM

EEFT

EGAN

ELME

ELVA

FBRT

FROG

GDDY

GEHC

GPMT

Hannon Armstrong Sustainable Infrastructure Capital

HASI

HIMX

HOUS

HTGC

IMPP

INFA

IRMD

ISSC

KELYA

KELYB

KNSL

LECO

LGCY

LPTH

NTWK

NVMI

Earnings Scheduled For February 13, 2025

PacBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>), a leader in high-quality, long-read sequencing, is proud to announce its critical role in a study to be published in Nature Genetics. The study, titled&nbsp;Synchronized long-read genome, methylome, epigenome, and transcriptome for resolving a Mendelian condition, showcases how researchers leveraged PacBio's advanced sequencing solutions, including the synchronized Fiber-seq and Kinnex (formerly MAS-seq) multiomic approach, to uncover the genetic and molecular basis of a rare and complex Mendelian condition.
In collaboration with the University of Washington and the Undiagnosed Diseases Network (UDN), the study applied PacBio's state-of-the-art Revio&#x2122; sequencing system to integrate long-read genomic, transcriptomic, methylomic, and epigenomic data in a synchronized analysis to analyze a 9-month-old patient with an unsolved condition involving bilateral retinoblastomas, developmental delays, and additional symptoms. Previous diagnostic methods, including short-read sequencing, were unable to provide an answer. With PacBio's innovative multiomic solutions, researchers identified a chromosome X;13 balanced translocation disrupting four key genes—each through a unique molecular mechanism.

Biotech

General

PacBio Announces Publication In Nature Genetics Study Using Advanced Sequencing To Uncover Genetic Basis Of Rare Mendelian Condition In 9-Month-Old Patient

Across the recent three months, 4 analysts have shared their insights on Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>), expressing a variety of opinions spanning from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $3.06, a high estimate of $6.00, and a low estimate of $1.75. This current average has decreased by 18.4% from the previous average price target of $3.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1737669645_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Pacific Biosciences. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$1.75</td>
<td>$2.25</td>
</tr>
<tr>
<td>John Sourbeer</td>
<td>UBS</td>
<td>Announces</td>
<td>Neutral</td>
<td>$2.00</td>
<td>-</td>
</tr>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$6.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$2.50</td>
<td>$2.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Pacific Biosciences. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Pacific Biosciences compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Pacific Biosciences's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Pacific Biosciences's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PACB/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Pacific Biosciences analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Pacific Biosciences: A Closer Look</h2>
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
<h3>Financial Milestones: Pacific Biosciences's Journey</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Negative Revenue Trend: Examining Pacific Biosciences's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -28.23% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Pacific Biosciences's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -151.94% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Pacific Biosciences's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -12.84%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Pacific Biosciences's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -4.1%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Pacific Biosciences's debt-to-equity ratio is notably higher than the industry average. With a ratio of 2.03, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Pacific Biosciences Stock

Pacific Biosciences of California shares are trading lower after Goldman Sachs cut its price target on the stock from $2.25 to $1.75.

Goldman Sachs analyst Matthew Sykes maintains Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) with a Neutral and lowers the price target from $2.25 to $1.75.

Goldman Sachs Maintains Neutral on Pacific Biosciences, Lowers Price Target to $1.75

Pacific Biosciences shares are trading lower after the company issued worse-than-expected preliminary Q4 revenue.

PacBio And Radboud UMC Published Study In American Journal Of Human Genetics

Health Care

Press Releases

PacBio and Radboud UMC Announce Remarkable Study Results Using HiFi Long Read Sequencing to Help Advance Rare Disease Diagnostics

PacBio Names Global Institute for Food Security as Canada's First Revio Certified Service Provider

PacBio Technology Powers Landmark Multiomic Study Published in Nature Genetics

Management

PacBio Announces Appointment of Chris Smith to Board of Directors

PacBio to Report Fourth Quarter 2024 Financial Results on February 13, 2025

PacBio Announces Appointment of David Ruggiero as Head of Global Sales & Service

PacBio Announces Fourth Quarter and Fiscal Year 2024 Financial Results

PacBio Grants Equity Incentive Award to New Employee

PacBio to Participate in TD Cowen's 45th Annual Health Care Conference

Scientists Solve One of Genomics' Biggest Challenges by Using HiFi Sequencing to Distinguish Highly Similar Paralogous Genes

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Atlantic International Corp. - Common Stock

Atlantic International

Azenta

BioLife Solutions

Codexis

Champions Oncology

Cytek Biosciences

CryoPort

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Evotec

Fortrea Holdings

Standard BioTools

Lifecore Biomedical

Mesa Laboratories

Maravai LifeSciences Holdings, Inc. - Class A common stock

Maravai LifeSciences

MaxCyte

Niagen Bioscience

OmniAb

Personalis

Quantum-Si Incorporated - Class A Common Stock

Quantum-Si

Quanterix

Rapid Micro Biosystems, Inc. - Class A Common Stock

Rapid Micro Biosystems

Sotera Health

Alpha Teknova

10x Genomics

Scotiabank

Piper Sandler

Goldman Sachs

Stephens & Co.

2025년 3월 21일 금요일, 캐시 우드가 이끄는 아크 인베스트는 몇 가지 주목할 만한 거래를 진행했으며, 여기에는 상당한 매수와 매도가 포함되었다.
아크 인베스트의 펀드는 이리듐 커뮤니케이션스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRDM#NASDAQ">IRDM</a>), 빔 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>), 퍼시픽 바이오사이언스 오브 캘리포니아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>), 및 앱시 코퍼레이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>)를 매수한 반면, 일루미나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), 리페어 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>), 암젠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), 및 비바 시스템즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>)의 주식을 매도했다.
IRDM 거래: 아크 인베스트의 ARK Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>), ARK Autonomous Technology &amp; Robotics ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKQ#BATS">ARKQ</a>), 및 ARK Space Exploration &amp; Innovation ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKX#BATS">ARKX</a>) 펀드가 이리듐 커뮤니케이션스의 주식 68,355주를 총 매수했다.
마지막 종가 27.65달러를 기준으로 매수한 주식들의 총 가치는 약 189만 달러이다.
BEAM 거래: 아크 인베스트의 ARKK 및 Ark Genomic Revolution ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>) 펀드가 총 28,717주의 빔 테라퓨틱스주식을 매수했다.
마지막 종가 23.3달러을 기준으로 매수한 주식들의 총 가치는 약 669,106달러이다.
PACB 거래: 아크 인베스트의 ARKK 펀드가 퍼시픽 바이오사이언스 오브 캘리포니아의 주식 243,300주를 매수했다.
마지막 종가 1.3달러를 기준으로 매수한 주식들의 총 가치는 약 316,290달러이다.
기타 주요 거래:
<ul>
<li>일루미나: 아크 인베스트는 ARKK와 ARKG를 통해 총 42,616주의 주식을 매도했다.</li>
<li>앱시 코퍼레이션: 아크 인베스트는 ARKG를 통해 71,392주의 주식을 매수했습니다.</li>
<li>리페어 테라퓨틱스: 아크 인베스트는 ARKG를 통해 54,786주의 주식을 매도했다.</li>
<li>암젠: 아크 인베스트는 ARKG를 통해 990주의 주식을 매도했다.</li>
<li>비바 시스템즈: 아크 인베스트는 ARKG를 통해 1,322주의 주식을 매도했다.</li>
</ul>
다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/03/44434973/tesla-record-highest-trade-ins-amid-backlash-against-ceo-elon-musk-surge-in-vandalism">테슬라, CEO 일론 머스크에 대한 반발과 기물 파손 급증 속 역대 최고 거래량 기록</a></li>
</ul>
면책 조항: 이 내용은 AI 도구의 도움을 받아 부분적으로 작성되었으며, Benzinga 편집자에 의해 검토되고 게시되었습니다.
사진 제공: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Pacific Biosciences

뉴스

에 대한 최신 뉴스 Pacific Biosciences (NASDAQ:PACB) 주식

토요일, 3월 22, 2025

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌